| 06/10 | GALAPAGOS : presents new data from the SELECTION Phase 3 program at the United European Ga.. |  |
| 06/10 | GALAPAGOS : announces completion of patient enrollment for DIVERSITY Phase 3 study with fi.. | |
| 04/10 | GALAPAGOS : presents new data from the SELECTION Phase 3 program at the United European Ga.. | |
| 04/10 | Galapagos Presents New Data from the Selection Phase 3 Program At the United European G.. | |
| 04/10 | GALAPAGOS : Completes Patient Recruitment In Late-Stage Inflammatory Bowel Disease Study | |
| 04/10 | GALAPAGOS : announces completion of patient enrollment for DIVERSITY Phase 3 study with fi.. | |
| 04/10 | Galapagos Announces Completion of Patient Enrollment for Diversity Phase 3 Study with F.. | |
| 21/09 | GALAPAGOS : increases share capital through subscription right exercises (Form 6-K) | |
| 21/09 | GALAPAGOS : N.V., - Galapagos increases share capital through subscription right exercises | |
| 21/09 | GALAPAGOS : Issues New Shares For Subscription Right Exercises | |
| 20/09 | GALAPAGOS : increases share capital through subscription right exercises | |
| 20/09 | GALAPAGOS : ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT O.. | |
| 17/09 | GALAPAGOS : N.v., - galapagos announces positive chmp opinion for jyseleca® (filgotinib) f.. | |
| 17/09 | GALAPAGOS : Gets European Medicines Agency's Positive Opinion on Ulcerative Colitis Drug C.. | |
| 17/09 | GALAPAGOS : Says it Received European Medicines Agency Positive Opinion for Ulcerative Col.. | |
| 17/09 | GALAPAGOS : Announces positive chmp opinion for jyseleca® (filgotinib) for the treatment o.. | |
| 17/09 | Galapagos Announces Positive CHMP Opinion for Jyseleca® for the Treatment of Adults wit.. | |
| 01/09 | GALAPAGOS NV : - Bionity - Galapagos announces planned retirement of CEO | |
| 01/09 | El apoyo, cuando nos retienen |  |
| 31/08 | GALAPAGOS : announces planned retirement of CEO (Form 6-K) | |
| 31/08 | Galapagos NV Announces Retirement of CEO Onno Van De Stolpe | |
| 31/08 | VISIÓN GENERAL DE LOS ETFS : ¡ Ámster-tadam ! | |
| 30/08 | ADRs Close Mostly Higher; Alibaba, Shell Trade Actively | |
| 30/08 | GALAPAGOS : CEO To Retire | |
| 30/08 | GALAPAGOS : announces planned retirement of CEO | |
| 30/08 | Galapagos NV CEO to Retire | |
| 30/08 | TOUR D'HORIZON DES ETF : Amster-tadam ! |  |
| 19/08 | GALAPAGOS : Shares Drop After Barclays Downgrade | |
| 19/08 | Le changement, c'est bientôt | |
| 19/08 | AVIS D'ANALYSTES DU JOUR : LVMH, Kering, Teleperformance, Galapagos, Carlsberg, Swatch, Le.. | |
| 18/08 | Six actions infréquentables en 2021 | |
| 09/08 | Resultados casi perfectos | |
| 09/08 | Des résultats presque parfaits | |
| 09/08 | AVIS D'ANALYSTES DU JOUR : Crédit Agricole, Stellantis, Daimler, Galapagos, Swissquote, IM.. | |
| 05/08 | Galapagos Nv Reports Earnings Results for the Second Quarter Ended June 30, 2021 | |
| 05/08 | GALAPAGOS : reports H1 financial results with refocused pipeline and operational progress | |
| 15/07 | Galapagos ADRs Down After Study Data | |
| 15/07 | SECTOR UPDATE : Health Care Stocks Flat To Lower Pre-Bell Thursday | |
| 15/07 | UPDATE : Galapagos Reports Results From Phase 1b Psoriasis Study -- Shares Slump in Pre-Ma.. | |
| 15/07 | GALAPAGOS NV : des résultats cliniques décevants | |
| 15/07 | GALAPAGOS : N.V., - Galapagos reports positive topline results with selective TYK2 inhibit.. | |
| 15/07 | GALAPAGOS : N.V., - Galapagos demonstrates early clinical activity with SIK2/3 inhibition .. | |
| 15/07 | GALAPAGOS : données de phase Ib positives en psoriasis | |
| 15/07 | GALAPAGOS : Drug Shown Safe In Three Clinical Studies | |
| 15/07 | GALAPAGOS' : Psoriasis Drug Shown Safe, Well-Tolerated in Early-Stage Study | |
| 14/07 | GALAPAGOS : demonstrates early clinical activity with SIK2/3 inhibition in inflammation (F.. | |
| 14/07 | GALAPAGOS : reports positive topline results with selective TYK2 inhibitor GLPG3667 in Pha.. | |
| 14/07 | GALAPAGOS : GLPG3667 Shows Positive Results in Psoriasis Patients, Reports Topline Results.. | |
| 14/07 | GALAPAGOS : demonstrates early clinical activity with SIK2/3 inhibition in inflammation | |
| 14/07 | GALAPAGOS : reports positive topline results with selective TYK2 inhibitor GLPG3667 in Pha.. | |
| 14/07 | Galapagos NV Demonstrates Early Clinical Activity with SIK2/3 Inhibition in Inflammatio.. | |
| 14/07 | Galapagos NV Reports Positive Topline Results with Selective TYK2 Inhibitor Glpg3667 in.. | |
| 12/07 | GALAPAGOS : Bowel Disease Drug Shows Effect In Post-Hoc Analyses Of Late-Stage Study | |
| 10/07 | GALAPAGOS : announces new data supporting rapid symptom improvement and sustained steroid-.. | |
| 10/07 | Galapagos Announces New Data Supporting Rapid Symptom Improvement and Sustained Steroid.. | |
| 23/06 | GALAPAGOS : announces departure of CSO Piet Wigerinck later this year (Form 6-K) | |
| 23/06 | GALAPAGOS : Chief Scientific Officer To Step Down | |
| 22/06 | GALAPAGOS : Chief Scientific Officer to Leave Company Later This Year | |
| 22/06 | Galapagos Announces Departure of CSO Piet Wigerinck | |
| 21/06 | GALAPAGOS NV(ENXTAM : GLPG) dropped from S&P Global 1200 | |
| 21/06 | GALAPAGOS NV(ENXTAM : GLPG) dropped from S&P International 700 | |
| 21/06 | GALAPAGOS NV(ENXTAM : GLPG) dropped from S&P EUROPE 350 - Pharmaceuticals, Biotechnology &.. | |
| 21/06 | GALAPAGOS NV(ENXTAM : GLPG) dropped from S&P EUROPE 350 - Health Care | |
| 21/06 | GALAPAGOS NV(ENXTAM : GLPG) dropped from S&P EUROPE 350 | |
| 08/06 | GALAPAGOS : increases share capital through subscription right exercises (Form 6-K) | |
| 07/06 | Galapagos increases share capital through subscription right exercises | |
| 04/06 | GALAPAGOS : SELECTION study on filgotinib in ulcerative colitis published in The Lancet (F.. | |
| 04/06 | GALAPAGOS : Anti-inflammatory Drug Jyseleca Sustains Efficacy in Maintenance Study | |
| 04/06 | Galapagos NV Announces That Primary and Secondary Endpoint Results from the Phase 3 SEL.. | |
| 28/05 | GALAPAGOS : to present data on rheumatoid arthritis at the upcoming European League Agains.. | |
| 27/05 | Galapagos NV to Present Data on Rheumatoid Arthritis At the Upcoming European League Ag.. | |
| 19/05 | GALAPAGOS : announces first patient enrolled in FILOSOPHY study to advance understanding o.. | |
| 19/05 | GALAPAGOS : Enrolls First Patient in Post-Approval Study of Arthritis Drug | |
| 18/05 | GALAPAGOS : Launches Phase 4 Study of Filgotinib Rheumatoid Arthritis Medication in Europe | |
| 18/05 | Galapagos Announces First Patient Enrolled in FILOSOPHY Study to Advance Understanding .. | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (België)
